PATENTSCOPE sera indisponible quelques heures pour des raisons de maintenance le mardi 19.11.2019 à 16:00 CET
Recherche dans les collections de brevets nationales et internationales
Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2005062977) ANTICORPS HUMAINS D'INTERNALISATION SPECIFIQUES DU CANCER DE LA PROSTATE
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

CLAIMS

What is claimed is:

1. An antibody that specifically binds and is internalized into a prostate cancer cell, said antibody comprising an antibody that specifically binds an epitope that is specifically bound by bound an antibody selected from the group consisting of A33 (SEQ LD NO:22), M10A12 (SEQ LD NO:23), M9E4 (SEQ LD NO:24), OA12 (SEQ ID NO:25), M11G12 (SEQ LD NO:26), M11F12 (SEQ LD NO:27), and CIO (SEQ LD NO:28).

2. The antibody of claim 1, wherein said antibody comprises at least one CDR found in Table 1 or Table 2.

3. The antibody of claim 1, wherein said antibody comprises at least two CDRs found in Table 1 or Table 2.

4. The antibody of claim 1, wherein said antibody comprises at least three CDRs found in Table 1 or Table 2.

5. The antibody of claim 1, wherein said antibody comprises a NH region comprising a least three CDRs found in Table 1.

6. The antibody of claim 1, wherein said antibody comprises a N region comprising a least three CDRs found in Table 2.

7. The antibody of claim 1, wherein said antibody comprises a NH region found in Table 1.

8. The antibody of claim 1, wherein said antibody comprises a VL region found in Table 2.

9. The antibody of claim 7, wherein said antibody comprises a VH region found in Table 1 and a VL region found in Table 2.

10. The antibody of claim 1, wherein said antibody comprises a sequence selected from the group consisting of SEQ LD ΝO:2, SEQ LD NO 3, SEQ LD NO 4, SEQ LD NO 5, SEQ LD NO 6, SEQ LD NO 7, SEQ LD NO 8, SEQ ID NO:9, SEQ LD NO: 10, SEQ LD NO:ll, SEQ LD NO:12, SEQ ID NO:13, SEQ LD NO:14, SEQ LD NO:15, and conservative substitutions thereof.

11. The antibody of claim 1, wherein said antibody comprises a sequence selected from the group consisting of SEQ LD NO:2, SEQ LD NO 3, SEQ LD NO 4, SEQ LD

NO 5, SEQ LD NO 6, SEQ LD NO 7, and SEQ LD NO 8 attached to a sequence selected from the group consisting of SEQ LD NO:9, SEQ LD NO: 10, SEQ LD NO: 11, SEQ LD NO: 12, SEQ LD NO: 13, SEQ LD NO: 14, and SEQ LD NO: 15.

12. The antibody of claim 1, wherein said antibody consists of a single chain human antibody selected from the group consisting of A33 (SEQ LD NO:22),

M10A12 (SEQ LD NO:23), M9E4 (SEQ LD NO:24), OA12 (SEQ LD NO:25), M11G12 (SEQ LD NO:26), M11F12 (SEQ LD NO:27), and CIO (SEQ LD NO:28).

13. The antibody of any one of claims 1 through 12, wherein said antibody is a single chain antibody.

14. The antibody of claim 13, wherein an antibody selected from the group consisting of a Fab, a (Fab')2, an scFv, and an (ScFv')2.

15. The antibody of any one of claims 1 through 12, wherein said antibody comprises a diabody.

16. A chimeric molecule, said molecule comprising an effector attached to an antibody of any one of claim 1 through 15.

17. The chimeric molecule of claim 16, wherein said effector is selected from the group consisting of an epitope tag, a second antibody, a label, a cytotoxin, a liposome, a radionuclide, a drag, a prodrag, a viral particle, a cytokine, and a chelate.

18. The chimeric molecule of claim 16, wherein said effector is an epitope tag selected from the group consisting of an avidin, and a biotin.

19. The chimeric molecule of claim 16, wherein said effector is a cytotoxin selected from the group consisting of a Diphtheria toxin, a Pseudomonas exotoxin, a ricin, an abrin, and a thymidine kinase.

20. The chimeric molecule of claim 16, wherein said effector is a chelate comprising a metal isotope selected from the group consisting of 99Tc, 203Pb, 67Ga, 68Ga,

72As, mIn, 113πTn, 97Ru, 62Cu, 6 1Cu, 52Fe, 52mMn, 51Cr, 186, Re, 188Re, 77As, 90Y, 67Cu, 169Er, 121Sn, 127Te, 142Pr, 143Pr, 198Au, 199Au, 161Tb, 109Pd, 165Dy, 149Pm, 151Pm, 153Sm, 157Gd, 159Gd, 161Ho, 172Tm, 169Yb, 175Yb, 177Lu, 105Rh, and mAg.

21. The chimeric molecule of claim 16, wherein said effector is a chelate comprising an alpha emitter.

22. The chimeric molecule of claim 23, wherein said alpha emitter is bismuth 213.

23. The chimeric molecule of claim 16, wherein said effector is a chelate comprising DOTA.

24. The chimeric molecule of claim 16, wherein said effector is a lipid or a liposome.

25. A pharmaceutical formulation said formulation comprising:
a pharmaceutically acceptable excipient and an antibody according to any one of claims 1 through 15.

26. That pharmaceutical formulation of claim 25, wherein said formulation is a unit dosage formulation.

27. A pharmaceutical formulation said formulation comprising:
a pharmaceutically acceptable excipient and a chimeric molecule according to any one of claims 16 through 24.

28. That pharmaceutical formulation of claim 27, wherein said formulation is a unit dosage formulation.

29. A method of inhibiting the growth or proliferation of a prostate cancer cell, said method comprising contacting said cell with an antibody of any one of claims 1 through 12.

30. The method of claim 29, wherein said cell is a metastatic cell.

31. The method of claim 29, wherein said cell is a solid tumor cell.

32. A method of inhibiting the growth or proliferation of a prostate cancer cell, said method comprising contacting said cell with chimeric molecule comprising an antibody according to any of claims 1 through 15 attached to a cytotoxin or a
radionuclide.

33. The method of claim 32, wherein said cell is a metastatic cell.

34. The method of claim 32, wherein said cell is a solid tumor cell.

35. A method of detecting a prostate cancer cell, said, said method comprising:
contacting said prostate cancer cell with a chimeric molecule comprising an antibody according to any of claims 1 through 15 attached to a detectable label; and
detecting the presence or absence of said detectable label.

36. The method of claim 35, wherein said detectable label is a selected from the group consisting of a gamma-emitter, a positron-emitter, an x-ray emitter, an alpha emitter, and a fluorescence-emitter.

37. A method of detecting a prostate cancer cell, said, said method method comprising:
contacting a prostate cancer cell with a chimeric molecule comprising an antibody according to any of claims 1 through 15 attached to an epitope tag;
contacting said chimeric molecule with a chelate comprising a detectable moiety whereby said chelate binds to said epitope tag thereby associating said detectable moiety with said chelate; and
detecting said detectable moiety.

38. The method of claim 37, wherein said detectable moiety is a radionuclide.

39. The method of claim 37, wherein said detectable moiety is selected from the group consisting of a gamma-emitter, a positron-emitter, an alpha emitter, an x-ray emitter, and a fluorescence-emitter.

40. The method of claim 37, wherein said detecting comprises external imaging.

41. The method of claim 37, wherein said detecting comprises internal imaging.

42. The method of claim 37, wherein said detectable moiety comprises a
oo ( fn fis n 11 1 metal isotope selected from the group consisting of Tc, Pb, Ga, Ga, As, Lα, 113πιln, 97Ru, 62Cu, 641Cu, 52Fe, 52mMn, 51Cr, 186, Re, 188Re, 77As, 90Y, 67Cu, 169Er, 121Sn, 127Te, 142Pr, 143Pr, 198Au, 199Au, 161Tb, 109Pd, 165Dy, 149Pm, 151Pm, 153Sm, 157Gd, 159Gd, 161Ho, 172Tm, 169Yb, 175Yb, 177Lu, 105Rh, and ιπAg.

43. The method of claim 37, wherein said chelate comprises DOTA.

44. The method of claim 37, wherein said epitope tag is an avidin or a biotin.

45. A nucleic acid comprising a nucleic acid that encodes an antibody according to any of claims claim 2 through 12.

46. An expression vector comprising the nucleic acid of claim 45.

47. A cell comprising the expression vector of claim 46.

48. A kit comprising a container containing an antibody of claim 1.

49. The kit of claim 48, further comprising an effector.

50. The kit of claim 49, wherein said effector comprises a chelate.

51. The kit of claim 48, wherein said antibody is in a pharmacologically acceptable excipient.